Patient Reported QoL for Docetaxel vs 177Lu-617-PSMA for #mCRPC: Results from the Canadian Cancer Trials Group PR21 Trial. Presented by @DKhalafMD. #ESMO26 written coverage by @zkl

UroToday.com· @urotoday · X·2026-10-24 05:45· 1 天前评分45

正文 · 原文

Patient Reported QoL for Docetaxel vs 177Lu-617-PSMA for #mCRPC: Results from the Canadian Cancer Trials Group PR21 Trial. Presented by @DKhalafMD. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4iDewfC #ProstateCancer #ClinicalTrials @myESMO

246 浏览 · 3 赞 · 2 转发 · 0 回复

会议摘要

2300TIPNCT07365995 NCT07365995 NCT07365995按 Metastatic prostate cancer 对上

BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer

https://esmocongress.esmo.org

LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：UroToday.com · x.com